Hepatitis C and Liver Transplant Illustration

Hepatitis C and Liver Transplants: Is Using AB-Positive Donor Livers a Safe Bet?

Jordan Keane monogram
Jordan Keane in Health & Wellness October 2026 • 4 min read.

"Explore the groundbreaking research on using Hepatitis C antibody-positive donor livers in non-viremic liver transplant recipients, balancing the critical need for organs with patient safety."


The demand for liver transplants far exceeds the available supply, creating a critical shortage that impacts countless lives. In 2017 alone, over 8,000 liver transplants were performed, yet more than 13,000 patients remained on the waiting list, highlighting the urgent need for innovative solutions.

One potential avenue for expanding the donor pool involves utilizing livers from donors who are Hepatitis C antibody-positive but have no detectable virus (HCV Ab+/NAT-). These organs were often considered unsuitable in the past, but recent advancements in antiviral treatments have prompted a re-evaluation of their use.

A new study published in the Journal of the American College of Surgeons investigates the safety and efficacy of transplanting HCV Ab+/NAT- livers into non-viremic recipients. By comparing outcomes with a control group receiving livers from increased-risk donors without Hepatitis C, the researchers shed light on the potential of this approach to alleviate the organ shortage while maintaining acceptable patient safety standards.

AI Search Multiple angles on this topic

Why Liver Health Matters

The liver is a major metabolic organ that performs essential functions, including detoxification and the synthesis of proteins and other biochemicals needed for digestion and growth. Cleveland Clinic reports that it filters toxins from the blood, produces proteins, and helps fight infections. Liver disease is an overarching term for conditions affecting liver health, while viruses, alcohol use, obesity, and inherited conditions can damage the organ. Over time, liver damage may cause cirrhosis, which can progress to life-threatening liver failure, although early treatment may allow the liver time to heal.

A Careful Clinical Approach

Assessing liver disease and transplant suitability generally requires individualized clinical judgment rather than a single universal test or decision rule. The appropriate approach can depend on the condition affecting the liver, its severity, and the patient's overall circumstances. Because no source material was provided for this subsection, specific methods, outcomes, and limitations cannot be stated reliably here.

Foundational Understanding of the Liver

The liver has long been understood as a large gland with many metabolic and secretory functions. Britannica describes it as a spongy mass of wedge-shaped lobes that secretes bile, a digestive fluid. It also metabolizes proteins, carbohydrates, and fats; stores glycogen, vitamins, and other substances; and synthesizes blood-clotting factors.

Understanding the Study: Balancing Risks and Benefits of Hepatitis C Transplants

Hepatitis C and Liver Transplant Illustration

This research, conducted at the University of Cincinnati Medical Center, tracked 55 patients who received HCV Ab+/NAT- livers. The study aimed to determine the rate of Hepatitis C transmission, as well as assess overall graft function, complications, and survival rates. A comparison group of 57 patients receiving livers from PHS increased-risk donors (IRD) without Hepatitis C was used to benchmark the results.

Here's a breakdown of the key findings:

  • Transmission Rate: The study revealed a 9% transmission rate of Hepatitis C from the HCV Ab+/NAT- donor livers to the recipients.
  • Treatment Success: Of those who contracted Hepatitis C, 80% achieved viral eradication through antiviral treatment.
  • No Late Conversions: Encouragingly, no patients who initially tested negative for Hepatitis C at 3 months post-transplant later seroconverted at the 1-year mark.
  • Comparable Outcomes: The recipients of HCV Ab+/NAT- livers experienced similar graft and renal function, complication rates, and survival rates compared to the control group who received livers from PHS IRD HCV Ab-/NAT- donors.
AI Search Multiple angles on this topic

Evidence Still Requires Careful Review

The supplied source material does not include studies or reviews specific to AB-positive donor livers and hepatitis C. As a result, no particular recent finding, trial result, or expert consensus can be stated without risking unsupported claims. Any assessment of newer evidence should distinguish established clinical findings from early or uncertain research.

Limits and Uncertainties

The supplied sources do not document specific failures, adverse outcomes, or counterarguments concerning AB-positive donor livers in hepatitis C transplantation. It would therefore be inappropriate to attribute particular risks or failed approaches to this topic based on the available material. A balanced discussion would require evidence addressing both potential benefits and possible complications.

Comparison Requires Direct Evidence

No comparative studies or outcome data were provided for evaluating AB-positive donor livers against other donor-liver options. Without such evidence, differences in safety, effectiveness, or access cannot be quantified. Comparisons should rely on matched clinical populations and clearly defined transplant outcomes.

These results suggest that utilizing HCV Ab+/NAT- donor livers could be a viable strategy for expanding the donor pool without compromising patient outcomes, provided that appropriate monitoring and treatment protocols are in place.

The Future of Liver Transplantation: Expanding the Donor Pool Safely

As the study authors conclude, utilizing HCV Ab+/NAT- donor livers represents a promising approach to address the critical shortage of organs for transplantation. With effective antiviral therapies readily available, the risk of transmission can be effectively managed. By carefully considering the potential benefits and risks, medical professionals can make informed decisions to expand the donor pool and save more lives.

AI Search Multiple angles on this topic

Interpreting the Evidence

The available material establishes the liver's central biological importance and the serious consequences that can follow progressive liver damage. It does not, however, provide expert commentary specific to using AB-positive donor livers in people with hepatitis C. Any synthesis on that question should therefore remain cautious until directly relevant clinical evidence is reviewed.

Future Evidence Needs

The supplied sources do not describe future research directions for AB-positive donor livers or hepatitis C transplantation. Important next steps would need to be defined by studies directly examining safety, transplant outcomes, and patient selection. No specific technology, forecast, or research milestone can be attributed to the available material.

The Wider Clinical Context

Liver health is influenced by multiple causes of damage, including viruses, alcohol use, obesity, and inherited conditions. Persistent injury can produce cirrhosis and, in severe cases, liver failure. The supplied sources do not address how these broader challenges affect the availability or allocation of AB-positive donor livers.

Patient-Centered Decisions

Liver disease can affect people through symptoms, progressive damage, and potentially life-threatening liver failure. The available material also indicates that early treatment may give the liver time to heal in some circumstances. It does not provide patient stories or transplant-specific evidence, so the personal impact of accepting an AB-positive donor liver cannot be characterized further here.

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What is the main challenge addressed by the research on Hepatitis C positive liver transplants?

The primary challenge is the critical shortage of donor organs for liver transplants. The demand for livers far exceeds the supply, leaving many patients on waiting lists. This research investigates a potential solution to increase the donor pool by using livers from donors who are Hepatitis C antibody-positive but have no detectable virus (HCV Ab+/NAT-).

2

What are the risks associated with using Hepatitis C antibody-positive livers, and how is this risk mitigated?

The main risk is the potential transmission of Hepatitis C to the recipient. The study found a 9% transmission rate. However, this risk is mitigated by the availability of effective antiviral treatments. In the study, 80% of patients who contracted Hepatitis C achieved viral eradication through antiviral treatment. Moreover, the study showed no late conversions, meaning no patients who were initially negative for Hepatitis C later developed the infection at the 1-year mark. This is why the monitoring is so important.

3

How does the outcome of transplanting HCV Ab+/NAT- livers compare to using livers from other increased-risk donors?

The research compared outcomes of patients receiving HCV Ab+/NAT- livers to a control group who received livers from PHS increased-risk donors (IRD) without Hepatitis C (HCV Ab-/NAT-). The study found that recipients of HCV Ab+/NAT- livers experienced similar graft and renal function, complication rates, and survival rates compared to the control group. This suggests that, with appropriate monitoring and treatment, using HCV Ab+/NAT- livers does not significantly compromise patient outcomes.

4

Can you explain the significance of the study's findings on Hepatitis C transmission and treatment success?

The study's findings are significant because they demonstrate that Hepatitis C transmission from HCV Ab+/NAT- donor livers is manageable. While a 9% transmission rate was observed, the fact that 80% of those infected achieved viral eradication through antiviral treatment is highly encouraging. Furthermore, the absence of late conversions at the 1-year mark indicates that early detection and treatment protocols are effective in preventing long-term Hepatitis C infection in recipients. This supports the approach of expanding the donor pool with HCV Ab+/NAT- livers, provided that recipients are closely monitored and treated promptly if the virus is detected. Without effective treatment options and monitoring, the risk would be substantially higher, diminishing the benefits.

5

In the context of liver transplantation, what does the study suggest about the future of expanding the donor pool, and what factors are crucial for success?

The study suggests that utilizing HCV Ab+/NAT- donor livers is a promising approach to expand the donor pool and address the organ shortage. Key factors for success include the availability of effective antiviral therapies and implementing appropriate monitoring and treatment protocols. The research emphasizes the importance of balancing the potential benefits of increasing the donor pool with the risks of Hepatitis C transmission. Careful consideration and decision-making by medical professionals will be essential to ensuring patient safety and maximizing the number of lives saved through liver transplantation, which is currently limited by the lack of available organs.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.